2024 Alzheimer’s disease facts and figures.
Alzheimer’s Association.
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Caraci F, Santagati M, Caruso G, et al. F1000Res. 2020;9:F1000 Faculty Rev-686.
Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial.
Cummings JL, Lyketsos CG, Peskind ER, et al. JAMA. 2015;314(12):1242-1254.
Longitudinal course of agitation and aggression in patients with Alzheimer's disease in a cohort study: methods, baseline and longitudinal results of the A3C study.
De Mauleon A, Delrieu J, Cantet C, et al. J Prev Alzheimers Dis. 2021;8(2):199-209.
Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia.
Halpern R, Seare J, Tong J, et al. Int J Geriatr Psychiatry. 2019;34(3):420-431.
Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease.
Herrmann N, Ruthirakuhan M, Gallagher D, et al. Am J Geriatr Psychiatry. 2019;27(11):1161-1173.
Assessment and management of behavioral and psychological symptoms of dementia.
Kales HC, Gitlin LN, Lyketsos CG. BMJ. 2015;350:h369.
The hyperactivity-impulsivity-irritiability-disinhibition-aggression-agitation domain in Alzheimer's disease: current management and future directions.
Keszycki RM, Fisher DW, Dong H. Front Pharmacol. 2019;10:1109.
Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial.
Lee D, Slomkowski M, Hefting N, et al. JAMA Neurol. 2023;80(12):1307-1316.
Interprofessional insights in agitation in Alzheimer's disease: an interview with the experts from Emory Integrated Memory Care.
Pettis J. Geriatr Nurs. 2024;59:697-700.
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Porsteinsson AP, Drye LT, Pollock BG, et al. JAMA. 2014;311(7):682-691.
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS, Tariot PN, Dagerman KS, et al. N Engl J Med. 2006;355(15):1525-1538.
Clinical Practice Guidelines
Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm.
Cummings J, Sano M, Auer S, et al. Int Psychogeriatr. 2024;36(4):251-262.
Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition.
Sano M, Cummings J, Auer S, et al. Int Psychogeriatr. 2024;36(4):238-250.
Patient and Caregiver Resources
Alzheimer’s Association
Agitation in Alzheimer’s Screener for Caregivers
Brexpiprazole Prescribing Information
US Food and Drug Administration